Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Cystitis 1

Interventions

Gemcitabine 30Mitomycin 25BCG Vaccine 11Docetaxel 10Epirubicin 6erdafitinib 5durvalumab 5Radiotherapy 5dodecyl maltoside 4apaziquone 4tislelizumab 3Cystoscopy 3ALT-803 3viscum album peptide 2pembrolizumab 2disitamab vedotin 2avelumab 2VB4-845 2Therapeutics 2Imiquimod 2Hyaluronic Acid 25-aminolevulinic acid hexyl ester 21-phenyl-3,3-dimethyltriazene 2vocimagene amiretrorepvec 1valrubicin 1tremelimumab 1toripalimab 1pirarubicin 1pemigatinib 1monalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Non-Muscle Invasive Bladder Neoplasms × lornoxicam × Clear all
NCT03038321 2017-05-23

Solifenacin, Levofloxacin or Lornoxicam, Which Is Ideal for Management of Intravesical Instillation BCG Side Effects?

Mansoura University

Phase 4 Unknown
150 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Cystitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡